Panacea Biotec hits 5% upper circuit after Mankind Pharma deal, Health Information, ET HealthWorld


New Delhi: Stocks of Panacea Biotec hit their upper circuit limits on Wednesday as Mankind Pharma introduced the purchase of Panacea’s method manufacturers.

Mankind Pharma will achieve Panacea Biotec Pharma’s formulations manufacturers for India and Nepal markets for Rs 1,872 crore. Following the replace, stocks of Panacea Biotec zoomed 5 in step with cent, its day by day circuit restrict, to Rs 198.50, prior to buying and selling at Rs 197.10 at 9.40 am. The scrip settled at Rs 189.05 on Monday.

BSE barometer and benchmark Sensex used to be buying and selling at 618.37 issues or 1.10 in step with cent decrease at 55,628.91 on the time of penning this file.

As a part of this association, Mankind Pharma is keeping Panacea’s gross sales and advertising workforce engaged within the specific trade.

Thru this acquisition, Mankind Pharma will be capable to discover new healing spaces and create visibility in way of life, oncology and transplant trade.

Beleaguered Panacea Biotec has been suffering to pay off a debt of Rs 750 crore to Piramal Enterprises and India Resurgence Fund (IndiaRF). The drug maker additionally has rights to fabricate Sputnik V Covid-19 vaccine.

In February, Serum Institute of India, which owned 8.59 in step with cent stake in Panacea Biotec in December 2021, offered 358,000 of its fairness stocks on NSE at Rs 278.15.





Source link

Posted on

Leave a Reply

Your email address will not be published.